The British Clinical Association (BMA) has backed proposals to permit the source of two progestogen-only contraceptive products in neighborhood pharmacies, but stated “some issues” have to have to be resolved just before the adjust is agreed.
In February 2021, the Medications and Health care solutions Regulatory Agency (MHRA) launched consultations on the reclassification of two progestogen-only contraceptive capsules — Lovima 75 microgram movie-coated tablets and Hana 75 microgram film-coated tablets — from prescription-only medications (POMs) to pharmacy (P) medicines.
It is the initial time a switch to creating the contraceptive merchandise readily available from pharmacies with out a prescription has been deemed.
Responding to the consultation, which shut on 5 March 2021, the BMA claimed it was “in favour” of the change as it would look for to address some of the barriers and wellbeing inequalities [women face], and was very likely to final result in a reduction in unplanned pregnancies.
Nevertheless, the affiliation stated it would be “pertinent” to deal with some issues relating to safeguarding and the opportunity for reduction of use of extended-performing reversible contraceptives (LARCS).
“One worry about pharmacies that supply some contraceptives is that they do not offer possibly a whole array of contraceptive solutions or in-depth counselling about the challenges and benefits of various choices,” the BMA response mentioned.
“LARCs are more efficient contraception than Lovima [and Hana], a contraceptive tablet, which is generally because of to user compliance, and we are anxious that devoid of enough information and facts, sensitive counselling and signposting to the right products and services, the usage of LARCs could fall as a outcome of this change.
“Such a decrease in LARCs use could have other unintended outcomes relating to unplanned pregnancies, maternal wellbeing and over and above.”
The BMA added that Lovima and Hana are only powerful as extended as a user remembers to take them.
“In addition, an once-a-year dialogue with folks receiving contraceptive providers was thought of adequately vital for it to have been incorporated in the Good quality and Outcomes Framework, and it ought to also be a prerequisite of Progestogen Only Capsule (POP) supply from pharmacies.”
The Enterprise Chemists’ Affiliation also supported the reclassification proposals, but agreed that checking needed to be “factored in” to display for adverse aspect outcomes.
“If the monitoring is to be carried out by the pharmacist, then this also needs to be factored into the model underneath which contraceptive P medications are sent.”
It included: “Training for pharmacy teams will require to be furnished prior to the start of P med desogestrel contraceptives so that they can present girls with the information and facts they will need to make an educated selection.”
Commenting on the consultations, Sandra Gidley, president of the Royal Pharmaceutical Modern society, explained: “We have welcomed this MHRA session, which could see a progestogen-only contraceptive tablet turn into out there without a prescription.
“The transfer will aid to maximize obtain to effective suggests of contraception by means of pharmacy and will give gals extra selections to enable them make educated choices on their medications with the advice of a pharmacist.”